[Skip to Content]
[Skip to Content Landing]
Citations 0
Letters
August 9, 2000

Estrogen-Progestin Replacement and Risk of Breast Cancer

Author Affiliations
 

Stephen J.LurieMD, PhD, Contributing EditorIndividualAuthorPhil B.FontanarosaMD, Executive Deputy EditorIndividualAuthor

JAMA. 2000;284(6):691-694. doi:10.1001/jama.284.6.691

To the Editor: While the conclusions of Dr Schairer and colleagues1 are supported by earlier studies,2 several clarifications would help the reader better interpret the data that are presented. First, the authors describe the patient groups in the follow-up study as (1) those who underwent breast surgery for benign disease, (2) those who had a surgical consultation but did not have a biopsy or aspiration, and (3) those without either surgery or recommendation for consultation. As the patients from these groups were at different risks for developing breast cancer, were the 3 groups equally represented across the different HRT categories? Additionally, do the authors have data about the type of benign breast disease found in the 25,114 women who underwent biopsy? This could be of potential importance, since the risk of subsequent development of cancer may be influenced by the type of benign breast disease.3,4

First Page Preview View Large
First page PDF preview
First page PDF preview
×